The WASP/WAVE proteins are considered potential therapeutic targets against PCa, with N-WASP believed to be a more potent activator of the ARP 2/3 complex compared to Cortactin (Burianek and Soderling, 2013; Mughees et al., 2021). Here, WASL is linked to posterior cortical atrophy.